Azficel-T

Drug Profile

Azficel-T

Alternative Names: Autologous human fibroblasts - Fibrocell Science; Azfibrocel-T; azficel-T fibroblast suspension; Fibroblast cell therapy - Fibrocell Science; Isolagen therapy; Laviv

Latest Information Update: 15 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Isolagen
  • Developer Fibrocell Science
  • Class Cell therapies; Fibroblast cell therapies; Skin disorder therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Dysphonia; Periodontal disorders; Scars

Highest Development Phases

  • Marketed Facial-wrinkles
  • Discontinued Dysphonia; Periodontal disorders; Scars

Most Recent Events

  • 21 Dec 2016 Fibrocell Science completes a phase II trial for Dysphonia in USA (Injection) (NCT02120781)
  • 07 Jul 2016 Fibrocell Technologies terminates phase II trial in Scars (Restrictive burn scars) in USA (NCT01858753)
  • 29 Jun 2016 Azficel-T is available for divestiture as of 29 Jun 2016. www.fibrocell.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top